Criteria for liver transplantation for HCC: what should the limits be?
- PMID: 21718672
- DOI: 10.1016/j.jhep.2011.05.012
Criteria for liver transplantation for HCC: what should the limits be?
Abstract
Liver transplantation is a well-established treatment in a subset of patients with cirrhosis and hepatocellular carcinoma. The Milan criteria (single nodule up to 5 cm, up to three nodules none larger than 3 cm, with no evidence of extrahepatic spread or macrovascular invasion) have been traditionally accepted as standard of care. However, some groups have proposed that these criteria are too restrictive, and exclude some patients from transplantation who might benefit from this procedure. Transplanting patients with tumors beyond the established criteria falls into two categories, those whose tumors are beyond the Milan criteria at presentation without the use of treatment prior to transplantation (expanded criteria), and those in whom treatment allows the Milan Criteria to be fulfilled (down-staging). Currently, however, there is no international consensus regarding these approaches in clinical practice. The purpose of this systematic review is to clarify this debate through a critical analysis of available data. Finally, some comments on predictive factors apart from morphological characteristics are also addressed.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
-
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19. Eur J Cancer. 2007. PMID: 17182241
-
Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.Health Technol Assess. 2007 Sep;11(34):1-206. doi: 10.3310/hta11340. Health Technol Assess. 2007. PMID: 17767898
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320. Health Technol Assess. 2001. PMID: 12065068
Cited by
-
Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma.J Oncol. 2019 Sep 16;2019:6298502. doi: 10.1155/2019/6298502. eCollection 2019. J Oncol. 2019. PMID: 31636667 Free PMC article.
-
Enlarged selection criteria for hepatocellular cancer: is the upper limit needed?Transl Gastroenterol Hepatol. 2017 Sep 21;2:73. doi: 10.21037/tgh.2017.09.02. eCollection 2017. Transl Gastroenterol Hepatol. 2017. PMID: 29034346 Free PMC article. Review.
-
HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma.Oncotarget. 2016 Sep 20;7(38):62789-62796. doi: 10.18632/oncotarget.11558. Oncotarget. 2016. PMID: 27566593 Free PMC article. Review.
-
Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC.PLoS One. 2013;8(1):e53960. doi: 10.1371/journal.pone.0053960. Epub 2013 Jan 22. PLoS One. 2013. PMID: 23349774 Free PMC article.
-
Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival.Medicine (Baltimore). 2020 Jul 10;99(28):e21161. doi: 10.1097/MD.0000000000021161. Medicine (Baltimore). 2020. PMID: 32664152 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical